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Background: Pneumoperitoneum-induced oxidative stress and organ injury are known to be associated with nitric
oxide (NO) inactivation. Because arginase competes with NO synthase (NOS) for a common substrate, L-arginine,
arginase inhibition may increase NO bioavailability. Therefore, we evaluated the ability of the arginase inhibitor, 2
(S)-amino-6-boronohexanoic acid (ABH), to attenuate pneumoperitoneum-induced decrease of NO bioavailability
and lung injury.
Methods: Thirty rats were randomly divided into the following groups: 1) the PP-ABH group received a
subcutaneous injection of ABH (5 mg/kg) 1 h before induction of pneumoperitoneum (insufflation to
intraperitoneal pressure of 15 mmHg for 60 min); 2) the PP group received saline by subcutaneous injection
1 h before induction of pneumoperitoneum; and 3) the control group received saline by subcutaneous
injection before a sham procedure with no gas insufflation. After desufflation, blood was collected to
determine levels of plasma nitrite, NOS, inflammatory cytokines, and malondialdehyde, a marker of oxidative
stress. Lung tissue was obtained for histological evaluation.
Results: We found that plasma nitrite levels were lower in the PP group and higher in the PP-ABH group, compared
with controls (P <0.01 and P <0.05, respectively). In the PP group, endothelial NOS activity was decreased and inducible
NOS activity was increased compared with the PP-ABH and control groups. Malondialdehyde levels increased 3-fold in
the PP group and 2-fold in the PP-ABH group compared with controls. Tumor necrosis factor-α, interleukin-6, and
interleukin-1ß levels were elevated in the PP group compared to the control group, but the increase in cytokine
production was attenuated or blocked in the PP-ABH group. Lung injury scores were 4.8-fold higher in the PP
group and 2-fold higher in the PP-ABH group compared with controls (P <0.001 and P <0.01, respectively).
Discussion: Pneumoperitoneum decreases NO bioavailability and increases the inflammation cytokines,
resulting in organ injuries. Inhibition of arginase activity could maintain NO bioavailability by attenuating
pneumoperitoneum-induced changes in NOS activity. In addition, arginase inhibition attenuated the oxidative
stress and inflammation and decreased the severity of lung injury caused by pneumoperitoneum.
Conclusions: By increasing NO bioavailability and suppressing oxidative stress and inflammation, pretreatment
with an arginase inhibitor may protect against lung injury caused by pneumoperitoneum.
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Compared with conventional open surgery, minimally
invasive surgery (e.g., laparoscopic and robotic surgery)
has considerable advantages including less pain, shorter
hospital stays, decreased morbidity, and more rapid re-
turn to full activity [1]. However, laparoscopic surgery is
not without physiologic derangement of internal organs.
Pneumoperitoneum required for laparoscopic visualization
results in significantly decreased blood flow to intraperito-
neal organs, which promotes anaerobic metabolism leading
to lactic acidosis, oxidative stress, and postoperative mani-
festations, such as oliguria and elevated liver enzymes [2].
In addition, postoperative decrease in organ function
is the major cause of laparoscopy-associated morbid-
ity and mortality [3]. Even short periods of pressure
as low as 10–15 mmHg cause organ hypoperfusion, leading
to postoperative tissue injury [4–6]. More serious concerns
have been raised about robot-assisted surgery, because it re-
quires steep or reverse Trendelenburg positions, which are
associated with higher risks of organ damage due to
changes in intraperitoneal pressure [2].
Mechanisms of organ injury during pneumope-
ritoneum include decreased nitric oxide (NO), sym-
pathetic hyperactivation, and oxidative stress [7–9].
Endothelial NO synthase (eNOS) produces most of
the NO in the vasculature, where it activates soluble
guanylyl cyclase and increases cyclic guanosine mono-
phosphate levels in smooth muscle cells to dilate
blood vessels [10]. In addition, NO inhibits platelet
aggregation and suppresses vascular smooth muscle
hyperplasia and its sensitivity to the sympathetic
nerve activity [11, 12]. Therefore, decreased NO bio-
availability directly causes vasoconstriction and indir-
ectly inhibits vasodilation via the autonomic nervous
system, resulting in increase in oxidative stress and
ischemic damage of not only the intraperitoneal organ
but the extraperitoneal organ as well [8].
Because eNOS competes with arginase for the substrate
L-arginine, arginase inhibition has the potential to increase
NO bioavailability [13]. The relationship between arginase
inhibition and enhanced NO production has been demon-
strated in animal studies using an arginase inhibitor or
arginase knock-out model [14]. We reasoned that the dele-
terious effects of pneumoperitoneum on tissue perfusion
could be attenuated by improving NO bioavailability.
Specifically, we hypothesized that administration of an
arginase inhibitor before pneumoperitoneum would
increase NO bioavailability, thereby attenuating the
pneumoperitoneum-induced lung injury. We tested our
hypothesis by evaluating plasma nitrite, oxidative stress
marker, inflammatory cytokines, and lung injury in a rat
model during carbon dioxide (CO2) pneumoperitoneum
with or without pretreatment with the arginase inhibitor 2
(S)-amino-6-boronohexanoic acid (ABH).Methods
Animals and experimental design
This study was approved by the Yonsei University Insti-
tutional Animal Care and Use Committee and was con-
ducted according to the established guiding principles
for animal research. All experiments were performed in
3- to 4-month-old male Sprague–Dawley rats weighing
250–320 g. The rats were housed individually, main-
tained at a constant temperature and humidity under a
12-h dark/light cycle, and allowed food and water ad
libitum. The rats were randomly divided into three
groups, each consisting of 10 rats: 1) the PP-ABH group
received a subcutaneous injection of ABH (5 mg/kg) 1 h
before induction of pneumoperitoneum; 2) the PP group
received a subcutaneous injection of saline 1 h before
induction of pneumoperitoneum; and 3) the control
group received saline only (pneumoperitoneum was not
induced).
Pneumoperitoneum
One hour after injection of ABH or saline, the rats were
anesthetized with inhaled sevoflurane and secured a su-
pine position on a thermostatically regulated heating pad
(37 °C). After tracheostomy the lungs were mechanically
ventilated with a volume-driven small-animal ventilator
(model 665A, Harvard Apparatus, Holliston, MA, USA).
Tidal volume was set 1 mL/100 g body weight, and
respiratory rate was adjusted to 55–60 breaths/min to
maintain end-tidal CO2 at 30–35 mmHg. Anesthesia was
maintained with 1.5–2.0 % (volume percent) sevoflurane
and 50 % oxygen in air. A Veress needle was then inserted
in each rat. The control group underwent a sham proced-
ure with no gas insufflation, maintaining intra-abdominal
pressure at 0 mmHg. To induce pneumoperitoneum in
the PP and PP-ABH groups, CO2 was insufflated using an
electronic laparoflator (Karl Storz GmbH, Tuttlingen,
Germany), maintaining intra-abdominal pressure at
15 mmHg. After 1 h of pneumoperitoneum or sham pro-
cedure, heparin was administered, and the rats were
euthanized by cervical dislocation. Blood and lung tissue
were obtained for analysis.
Western blotting analysis for expression of NOS and
arginase II
Lung tissue specimens were thawed and homogenized in
ice-cold protein extraction buffer (Pro-prep, Intron Bio-
technology, Seoul, Korea). The protein samples were sepa-
rated by 8 %–10 % SDS-polyacrylamide gel electrophoresis,
and then transferred to a 0.2-μm polyvinyl-difluoride mem-
brane (Immun-Blot, Bio-Rad, CA, USA). The membranes
were blocked using 5 % (wt/vol) nonfat milk in Tris-
buffered saline with 0.1 % Tween-20, and then incubated
overnight at 4 °C with polyclonal antibodies (1:1000 dilu-
tion) against inducible NOS (iNOS; Abcam®, UK), eNOS
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Cruz Biotechnology). The bound antibody was detected
with labeled anti-rabbit secondary antibodies (1:5000 dilu-
tion) and visualized using the ECL Plus chemiluminescence
assay (Amersham Biosciences, CA, USA). Protein expres-
sion was normalized to β-actin (1:1000 dilution).
Arginase assay for arginase II activity
Activity of intracellular arginase was determined using
the QuantiChrom™ arginase assay kit (BioAssay Sys-
tems, CA, USA), which measures the conversion of
arginine to urea by arginase. Lung tissue was soni-
cated for 10 min in lysis buffer (50 mmol Tris–HCl,
pH 7.5, 0.1 mmol EDTA, 0.1 % Triton X-100, and
protease inhibitor) and centrifuged for 30 min at
14,000 × g at 4 °C. The supernatant (50 μL) was
added to 75 μl Tris–HCl (50 nmol, pH 7.5) contain-
ing 10 mmol MnCl2, and the mixture was activated
by heating at 55–60 °C for 10 min. The mixture was
incubated with 50 μL L-arginine (0.5 M, pH 9.7) at
37 °C for 2 h, and the reaction was stopped by add-
ing 400 μL acid solution (H2SO4:H3PO4:H2O, 1:3:7).
For the colorimetric determination of urea, 25 μL α-
isonitrosopropiophenone (9 % in ethanol) was added,
and the mixture was heated at 100 °C for 45 min.
After holding the reaction mixture in the dark for
10 min at room temperature, the urea concentration
was determined spectrophotometrically by measuring
absorbance at 430 nm.
Griess nitrite assay
To measure plasma nitrite (NO2
−), blood was collected in
tubes containing anticoagulants (citrate and EDTA). The
tubes were centrifuged for 15 min at 1000 × g, and the
plasma was incubated with 100 μL Griess reagent (1 %
sulfanilamide in 0.1 mol/l of HCl and 0.1 % N-(1-naphthyl)
ethylene diamine dihydrochloride) (Sigma-Aldrich, St.
Louis, MO, USA) at room temperature for 10 min.
Absorbance at 540 nm was measured using a microplate
reader, and nitrite content was calculated based on a stand-
ard curve constructed using NaNO2.
Enzyme-linked immunosorbent assay for NOS activity
The activities of eNOS and iNOS were determined using
rat eNOS and iNOS enzyme-linked immunosorbent assay
(ELISA) kits (Yuhan EIAabscience, Korea). In brief, lung
tissue specimens were homogenized in ice-cold Pro-Prep,
and the supernatant was incubated in a 96-well plate con-
taining co-factors and the substrate L-arginine at 37 °C.
After 1 h, the reaction was quenched by adding the stop
buffer. The concentrations of nitrites and nitrates in the re-
action mixture were determined using a colorimetric
method (530 nm).ELISA for oxidative stress marker malondialdehyde
To assess oxidative stress in the lung tissue, we evaluated
malonyldialdehyde (MDA), which is a stable product of
lipid peroxidation that is used as an index of oxygen free
radical production. The MDA content in lung tissue was
measured using an OxiSelect™ MDA Adduct ELISA kit
(Cell Biolabs, Inc., CA, USA). After adding the stop solu-
tion to halt the enzymatic reaction, absorbance at 450 nm
was measured using a spectrophotometer.
ELISA for proinflammatory cytokines
Commercially available ELISA kits were used to determine
serum levels of tumor necrosis factor (TNF)-α (BD Biosci-
ences, CA, USA), interleukin (IL)-1β (eBioscience, CA,
USA), and IL-6 (Young In Frontier Co., Ltd., Korea). In
brief, supernatants of lung tissue were added to a 96 well
plate coated with corresponding antibodies to each cyto-
kine and incubated. Streptavidin-horseradish peroxidase
conjugate was added as an antibody to a second epitope on
each cytokine. Absorbance was read by a microplate reader
using 450 nm as the primary wave length after adding the
stop solution.
Lung histology
Lung tissue specimens obtained from the left lower lobe
were fixed with 3 % paraformaldehyde, embedded in par-
affin, and then stained with hematoxylin and eosin. Lung
injury was assessed by a pulmonologist, who was blind to
the group allocation using the modified scoring system
described by Kristof et al. [15]. The level of lung injury
was graded as none (0), mild (1), moderate (2), or severe
(3) for each of the following three categories: interstitial
cellular infiltration, alveolar protein exudation, and tissue
hemorrhage. For each rat, 10 microscopic fields were
randomly selected (200× magnification). The score for
each category was determined by adding the scores from
the 10 different microscopic fields, and the total lung
injury score for each rat was calculated as a sum of the
three category scores.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). Groups were compared by one-way analysis
of variance for multiple comparisons (Tukey’s post hoc
test). Nonparametric data were analyzed by chi-square
test. Statistical analysis was conducted using Prism 5.01
software (GraphPad software Inc. CA, USA); P <0.05 was
considered significant.
Results
ArginaseIIexpression and activity
Results of western blot analysis showed that arginase II
expression in the lung tissue was comparable among the
three groups of rats (Fig. 1a). However, arginase II activity
Fig. 1 Arginase II expression and activity. a Arginase II expression did not differ significantly among the treatment groups. b However, arginase II activity
was increased significantly in the PP group compared with the PP-ABH and control groups. **P <0.01
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peritoneum (PP group), compared with those pretreated
with ABH before pneumoperitoneum induction (PP-ABH
group) and untreated controls (1.70 ± 0.60 U/L vs. 0.72 ±
0.25 U/L and 0.56 ± 0.31 U/L, respectively, P < 0.01 in
both) (Fig. 1b).NO bioavailability
Level of plasma nitrite, a stable metabolite of NO, was
significantly lower in the PP group compared with the PP-
ABH and control groups (19 ± 6.1 μmol/L vs. 60 ±
1.3 μmol/L and 42 ± 9.0 μmol/L, respectively, P <0.001
and P <0.01, respectively) (Fig. 2). In addition, plasma
nitrite level was higher in the PP-ABH group compared
with the control group (P <0.05).Fig. 2 Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO,
was decreased in the PP group but increased in the PP-ABH group
compared to controls. *P <0.05, **P <0.01, ***P <0.001NOS expression and activity
Results of western blot analysis showed that eNOS and
iNOS levels in the lung tissues were comparable among the
three treatment groups (Fig. 3a). However, eNOS activity,
as assessed by ELISA, was significantly lower in the PP
group compared with the PP-ABH and control groups
(2.8 ± 1.3 U/L vs. 14 ± 5.4 U/L and 11 ± 3.5 U/L, respect-
ively, P <0.01 and P <0.05, respectively) (Fig. 3b). Similarly,
iNOS activity in the lung tissue was significantly higher in
the PP group compared with the controls (19 ± 6.0 U/L vs
4.3 ± 1.9 U/L, P <0.001), but this increase was prevented
in the PP-ABH group (11 ± 3.5 U/L).
Oxidative stress
Results of ELISA showed that MDA content in lung tissues
was higher in the PP and PP-ABH groups compared with
the control group (50 ± 12 pmol/mg and 33 ± 8.1 pmol/mg
vs. 17 ± 5.0 pmol/mg, respectively, P <0.001 and P <0.05,
respectively), with higher MDA levels observed in the PP
group than in the PP-ABH group (P <0.05) (Fig. 4).
Inflammatory cytokines
Results of ELISA showed that TNF-α expression was
higher in the PP and PP-ABH groups compared with
controls (25 ± 5.4 pg/mL and 16 ± 5.2 pg/mL vs. 7.1 ±
2.1 pg/mL, respectively, P <0.001 and P <0.05, respect-
ively), with higher TNF-α levels observed in the PP
group than in the PP-ABH group (P <0.05). Levels of
both IL-6 and IL-1β were significantly higher in the PP
group compared with the PP-ABH and control groups
(Fig. 5).
Lung injury
Results of histologic analysis showed increased cellularity in
the PP group (P <0.001) and PP-ABH group (P <0.05)
Fig. 3 Expression and activity of endothelial and inducible nitric oxide synthase. a Expression of endothelial nitric oxide synthase (eNOS) and inducible
nitric oxide synthase (iNOS) did not differ significantly among the three treatment groups. b However, eNOS activity was significantly lower and iNOS
activity was higher in the PP group, compared with the PP-ABH and control groups. *P <0.05, **P <0.01, ***P <0.001
Fig. 4 Oxidative stress. Levels of the oxidative stress marker
malondialdehyde (MDA) were increased in the PP and PP-ABH groups
compared to the control group, and were higher in the PP group than
in the PP-ABH group. *P <0.05, ***P <0.001
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greater in the PP group than in the PP-ABH group
(P <0.001). Protein exudation was increased in the PP
group compared the control (P <0.001) and PP-ABH
groups (P < 0.01), but the degree of hemorrhage was
similar among the three groups. The total lung injury
scores (sum of cellularity, protein exudate, and
hemorrhage scores) were 4.8-fold higher in the PP
group (P <0.001) and 2-fold higher in the PP-ABH
group (P <0.01) compared to the control group. The
total lung injury score was significantly higher in the
PP group than in the PP-ABH group (P <0.001)
(Fig. 6, Table 1).
Discussion
The main finding of this study was that administra-
tion of the arginase inhibitor ABH attenuated the
pneumoperitoneum-induced decrease in NO bioavail-
ability in rats. In addition, ABH maintained the
activities of eNOS and iNOS; attenuated the increase
Fig. 5 Inflammatory cytokines. a Serum levels of TNF-α were increased in the PP and the PP-ABH groups compared with the control group, and
were higher in the PP group than in the PP-ABH group. b IL-6 and c IL-1β were increased significantly in the PP group compared with the
PP-ABH and control groups. *P <0.05, **P <0.01, ***P <0.001
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inflammatory cytokines TNF-α, IL-6, and IL-1β; and
decreased the severity of lung injury caused by
pneumoperitoneum.
Although pneumoperitoneum is essential for adequate
visualization during laparoscopic surgery, the resulting
derangement in organ function contributes to morbidity
and mortality. The protective role of NO in maintaining
organ function has been demonstrated in several studies.
NO maintains the organ blood flow. Organ hypoperfu-
sion during pneumoperitoneum can be attenuated by
pretreatment with the NO substrates nitroglycerine and
ethyl nitrite, but is exacerbated by administration of the
NOS inhibitor NG-nitro-L-arginine methyl ester [6, 16].
In addition, NO protects the cardiovascular system by
inhibiting norepinephrine secretion and decreasing the
response of vascular smooth muscle to the sympathetic
nervous system activity [12]. Furthermore, NO exerts
anti-inflammatory and anti-thrombotic effects through
the inhibition of leukocyte adhesion and platelet aggre-
gation, thereby protecting against vascular diseases suchFig. 6 Lung histology. a Normal lung histology in the control group. b Lun
protein exudation. c Pneumoperitoneum-induced inflammatory changes an
Hemorrhage levels were comparable among the three groupsas atherosclerosis [17, 18]. The predominant isoform of
NOS is eNOS, which keeps blood vessels dilated, con-
trols blood pressure, and has vasoprotective and anti-
atherosclerotic effects [11]. In contrast, iNOS is induced
by inflammatory cytokines, and NO produced by iNOS
has cytostatic effects, contributing to the pathophysi-
ology of inflammatory disease and septic shock [19]. In
this study, pneumoperitoneum led to a decrease in
eNOS activity and increase in iNOS activity, resulting in
decreased NO bioavailability.
By competing with NOS for the substrate L-arginine,
arginase acts as a critical regulator of NO synthesis [20].
Thus, arginase activity inhibits NO production [19], thereby
decreasing NO levels and increasing superoxide, which can
cause endothelial dysfunction [21]. Previous studies have
reported that inhibition or knock-out of arginase decreases
atherosclerosis and protects against myocardial ischemia-
reperfusion injury [14, 22, 23]. Our results showed that NO
bioavailability and eNOS activity were higher in rats that
received ABH before pneumoperitoneum compared with
those that did not receive ABH before pneumoperitoneum.g tissue in the PP group shows inflammatory cell infiltration and
d protein exudation were attenuated in the PP-ABH group.
Table 1 Lung injury scores described by Kristof scoring system
Cellularity Protein exudation Hemorrhage Total score
Control 1.3 ± 0.58 0.66 ± 0.44 0.84 ± 0.36 2.9 ± 0.97
PP 7.4 ± 1.4*** 4.8 ± 1.2*** 1.4 ± 0.9 14 ± 1.4***
PP-ABH 3.4 ± 1.1*, ***** 2.1 ± 0.93**** 0.9 ± 0.43 6 ± 1.4**, *****
*P <0.05, **P <0.01, ***P <0.001 compared with the control group
****P <0.01, *****P <0.001 compared with the PP group
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maintain NO bioavailability by preventing or attenuating
pneumoperitoneum-induced changes in NOS activity.
It is well known that pneumoperitoneum-induced
organ injury occurs not only in the intraabdominal
organs, but also in the extraabdominal organ, such as
lung. Pneumoperitoneum-induced oxidative stress and
lipid peroxidation were identified as components of lung
injury after pneumoperitoneum. The decrease of antioxi-
dant renders cells or tissues more susceptible to reactive
oxygen species attack [24] and lipid peroxidation results
in the damage of biological membrane and therefore cell
damage and tissue injury [25]. In addition, abdominal
deflation at the end of a laparoscopic procedure provides
a model of reperfusion damage in previously ischemic
organs, aggravating the oxidative stress and lipid peroxi-
dation [26]. Even when pneumoperitoneum was main-
tained at low pressure of 6 mmHg for 20 min, MDA and
oxidatively modified proteins were increased in the lungs
in rats [25]. With CO2 pneumoperitoneum maintained
at 15 mmHg for 30 min, intra-alveolar hemorrhage,
dense congestion, and leukocyte infiltration were found
in the lungs in rats [27].
In addition, pneumoperitoneum increases the inflamma-
tion cytokine [9], which leads to the release of local media-
tors such as platelet-activating factors and reactive oxygen
species, which cause damage to cell structures, capillary
endothelium, and pulmonary tissue, resulting in lung injury
[28]. Consistent with these previous findings, the levels of
the oxidative stress marker MDA and inflammatory cyto-
kines were increased by pneumoperitoneum in this study.
Administration of a drug with anti-oxidant and anti-
inflammatory effects was demonstrated to reduce the sever-
ity of pneumoperitoneum-associated lung injury [27, 29]. In
this study, the pretreatment of arginase inhibitor before
pneumoperitoneum partially or completely blocked the
increase of oxidative stress and inflammation, and these
anti-oxidant and anti-inflammatory effects might contribute
to the decrease of lung injury.
As another possible mechanism to reduce lung injury,
arginase inhibitor reduced iNOS activity. Oxidative stress is
resulted from overproduction of reactive oxidative species,
such as superoxide anion (O2
−), which inactivates NO and
diminishes its protective function [30]. Although NO pro-
tects against lung injury by inhibiting neutrophil migration
and NF-κB activity [31, 32], excessive NO production byiNOS is associated with the development of lung injury in
septic condition [33, 34]. In our results, the increased NO
bioavailability and attenuated iNOS activity induced by the
arginase inhibitor likely contribute to the reduction in lung
injury.
This study has several limitations. Firstly, we decided the
abdominal pressure at 15 mmHg, which was previously
reported to induce oxidative injury in lung tissue in rats
[8, 27]. In human, insufflation pressure is generally set at
less than 12 mmHg, not to raise the intraabdominal pres-
sure above that of the normal portal circulation pressure.
Especially in surgical intensive care units, intra-abdominal
pressure is tried to be maintained less than 12 mmHg to
prevent abdominal compartment syndrome, where the
detrimental effects of increased intra-abdominal pressure
are frequently observed [35]. In this study, intraabdominal
pressure was set at a higher level than usual to find out the
effect of arginase inhibitor on pneumoperitoneum-induced
organ injury. Although the majority of the studies investi-
gating oxidative stress associated with pneumoperitoneum
in rats have used the pressure of 12–15 mmHg, there is a
possibility that these high pressures might exaggerate
oxidative stress. In a rat model, pressures ≥ 8 mmHg are
above the peritoneal capillary occlusion pressure and the
optimal insufflation pressure to simulate human laparos-
copy is known to approximate 5 mmHg [36]. In addition,
the insufflation flow rate is also needed to be scaled down
for rat size not to exaggerate oxidative stress. To apply our
results to the clinical setting, further study is warranted in
a rat model with physiologically relevant gas pressure and
flow, which simulate the standard working conditions in
humans. Secondly, although all study groups received
mechanical ventilation with the same setting, elevated
intraabdominal pressure might displace the diaphragm in
a cephalad direction and increase intrathoracic pressure in
the pneumoperitoneum-induced groups, which might
influence lung injury. Thirdly, in addition to arginase and
NOS, agmatine was reported to involve in the arginine-
dependent pathways [37]. Agmatine is decarboxylated
arginine, and thus agmatine biosynthesis competes with
nitrogen metabolism by arginase and NO synthesis by
NOS. Agmatine is induced in response to stress and/or in-
flammation and modulates NO synthesis by inhibition of
neuronal NOS and iNOS and induction of eNOS. Further
research is needed to elucidate the change of agmatine
and the interaction among agmatine, NOS and arginase
during pneumoperitoneum.
Conclusions
In conclusion, our results show that pneumoperitoneum
led to a decrease in eNOS activity and increase in iNOS
activity, which might contribute to decreased NO bioavail-
ability. Pretreatment with the arginase inhibitor, ABH, pre-
vented these changes, and partially or completely blocked
Cho et al. BMC Anesthesiology  (2015) 15:129 Page 8 of 9pneumoperitoneum-induced oxidative stress and inflam-
mation, and decreased the severity of lung injury. Although
these findings are not applicable to clinical practice, they
indicate the potential of arginase inhibitors in reducing
pneumoperitoneum-associated organ injury in laparo-
scopic surgery.
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